查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1465205

依替巴肽市場：按類型、按應用分類 - 2024-2030 年全球預測

Eptifibatide Market by Type (0.75mg/ml Eptifibatide, 2mg/ml Eptifibatide), Application (Myocardial Infarction, Unstable Angina) - Global Forecast 2024-2030
出版日期: | 出版商: 360iResearch | 英文 184 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計2023年埃替巴肽市場規模為38,982萬美元，預計2024年將達4,1106萬美元，2030年將達57,729萬美元，複合年成長率為5.76%。

Eptifibatide 是一種環狀七勝胜肽，源自東南部侏儒響尾蛇 (Sistrurus miliarius barbouri) 毒液中的蛋白質。依替巴肽是一種血小板凝集抑制劑，在預防血栓形成中發揮重要作用，廣泛用於經經皮冠狀動脈成形術（PCI）。心血管疾病盛行率的顯著增加以及易患心臟病的老年人口數量的增加正在推動全球對依替巴肽的需求。經經皮治療 (PCI) 手術的進步正在推動依替巴肽使用的創新。有利的報銷政策和不斷成長的醫療保健支出也對市場擴張做出了重大貢獻。儘管存在成長前景，但與依替巴肽相關的顯著副作用（包括出血風險）可能會阻礙市場採用。遵守嚴格的監管標準也是市場拓展的一大挑戰。此外，藥物配方和藥物傳輸技術的不斷進步也凸顯了潛在發展和成長的領域。持續的研究和開發工作探索依替巴肽與其他抗血小板藥物的協同組合可能會開闢新的市場滲透途徑。

主要市場統計
基準年[2023] 38982萬美元
預測年份 [2024] 41106萬美元
預測年份 [2030] 57729萬美元
複合年成長率（%） 5.76%

2mg/ml 型製劑日益成為急性期給藥的首選

0.75 mg/ml 依替巴肽製劑通常在一段時間內連續輸注，通常先大劑量投藥，然後維持劑量。 0.75mg/ml特別適合因體重或腎功能等某些臨床因素而需要較低劑量的患者。 0.75 mg/ml 配方可達到精確劑量，通常用於需要滴定或逐漸減少抗血小板作用的治療方案。依替巴肽 2 mg/ml 製劑專為需要快速抑制血小板的高壓力情況下的急性給藥而設計，例如經皮冠狀動脈經皮治療 (PCI) 期間和之後立即給藥。高濃度允許快速推注，然後進行維持大劑量投藥，維持輸注可根據臨床反應和患者狀況進行調整。

應用型心肌梗塞的多種應用

依替巴肽作為治療方法的一部分給予，透過防止進一步形成血栓來降低隨後發生心血管事件的風險。在心肌梗塞病例中基於需求的依替巴肽偏好源於其在經皮冠狀動脈介入治療（PCI）期間改善患者預後的功效。不穩定型心絞痛是一種由心臟血流量減少引起的胸痛，是依替巴肽的另一個重要應用領域。與心肌梗塞類似，依替巴肽的作用是防止血小板凝集，進而降低心臟病發作的風險。

區域洞察

在美洲，特別是在美國和加拿大，依替巴肽的使用受到先進的醫療基礎設施和心血管疾病高盛行率的嚴重影響。在美國和加拿大，專利懸崖正在增加學名藥的使用並影響客戶的購買行為。在歐盟（EU），由於人口老化和心血管疾病的增加，依替巴肽的需求很大。歐洲國家擁有發達的醫療保健系統，降低醫療成本的努力正在影響依替巴肽的市場動態。醫療基礎設施相對發達、收入水平較高的中東地區對包括依替巴肽在內的先進治療方案的需求正在增加。有限的醫療設施和負擔能力問題限制了依替巴肽在非洲市場的採用。在亞太地區，中國、日本、印度等國家由於人口眾多、心血管疾病發生率不斷上升，在依替巴肽市場中佔有至關重要的地位。受政府改善醫療保健和促進依替巴肽等藥物本地生產措施的影響，中國市場正在快速成長。日本擁有先進的醫療保健系統，仍然是專注於創新治療解決方案的重要消費國。印度市場的特點是醫療保健意識不斷增強且價格低廉，學名藥正在推動亞太地區的市場成長。

FPNV定位矩陣

FPNV定位矩陣對於評估依替巴肽市場至關重要。我們檢視與業務策略和產品滿意度相關的關鍵指標，以對供應商進行全面評估。這種深入的分析使用戶能夠根據自己的要求做出明智的決策。根據評估，供應商被分為四個成功程度不同的像限：前沿（F）、探路者（P）、利基（N）和重要（V）。

市場佔有率分析

市場佔有率分析是一種綜合工具，可以對依替巴肽市場供應商的現狀進行深入而詳細的研究。全面比較和分析供應商在整體收益、基本客群和其他關鍵指標方面的貢獻，以便更好地了解公司的績效及其在爭奪市場佔有率時面臨的挑戰。此外，該分析還提供了對該行業競爭特徵的寶貴見解，包括在研究基準年觀察到的累積、分散主導地位和合併特徵等因素。詳細程度的提高使供應商能夠做出更明智的決策並制定有效的策略，從而在市場上獲得競爭優勢。

本報告在以下方面提供了寶貴的見解：

1. 市場滲透率：提供有關主要企業所服務的市場的全面資訊。

2. 市場開拓：我們深入研究利潤豐厚的新興市場，並分析其在成熟細分市場的滲透率。

3. 市場多元化：提供有關新產品發布、開拓地區、最新發展和投資的詳細資訊。

4. 競爭評估和情報：對主要企業的市場佔有率、策略、產品、認證、監管狀況、專利狀況和製造能力進行全面評估。

5. 產品開發與創新：提供對未來技術、研發活動和突破性產品開發的見解。

本報告解決了以下關鍵問題：

1. 依替巴肽市場規模及預測是多少？

2.依替巴肽市場預測期間有哪些產品、細分市場、應用和領域值得考慮投資？

3.依替巴肽市場的技術趨勢和法規結構是什麼？

4.依替巴肽市場主要廠商的市場佔有率是多少？

5. 進入依替巴肽市場的合適型態和策略手段是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 心血管疾病發生率上升，易患心臟病的老年人口增加
      • 經經皮冠狀動脈介入治療 (PCI) 技術的持續進步
      • 醫療費用上漲和有利的報銷政策
    • 抑制因素
      • 與使用依替巴肽相關的副作用和安全風險
    • 機會
      • 藥物配方和給藥技術的不斷進步
      • 研發活動持續追求與其他抗血小板藥物的協同效應
    • 任務
      • 遵守嚴格的監管標準
  • 市場區隔分析
    • 類型：2mg/ml 製劑越來越適合急性給藥
    • 應用：心肌梗塞的多種應用範圍
  • 市場擾動分析
  • 波特五力分析
  • 價值鍊和關鍵路徑分析
  • 價格分析
  • 技術分析
  • 專利分析
  • 貿易分析
  • 法規結構分析

第6章依替巴肽市場：依類型

  • 0.75mg/ml依替巴肽
  • 2mg/ml依替巴肽

第7章依替巴肽市場：依應用分類

  • 心肌梗塞
  • 不穩定型心絞痛

第8章 美洲依替巴肽市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第9章亞太依替巴肽市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第10章 歐洲、中東和非洲依替巴肽市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第11章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
    • 新研究發現抗血小板治療可改善致命性腦出血患者的預後
    • 加拿大醫院因關鍵藥物短缺而苦苦掙扎，朱諾製藥公司獲得依替巴肽進口核准
  • 戰略分析和建議

第12章競爭產品組合

  • 主要企業簡介
  • 主要產品系列
Product Code: MRR-6D54EA0F945B

[184 Pages Report] The Eptifibatide Market size was estimated at USD 389.82 million in 2023 and expected to reach USD 411.06 million in 2024, at a CAGR 5.76% to reach USD 577.29 million by 2030.

Eptifibatide is a cyclic heptapeptide derived from a protein found in the venom of the southeastern pygmy rattlesnake (Sistrurus miliarius barbouri). Eptifibatide is a platelet aggregation inhibitor playing a significant role in preventing blood clots and is widely used during percutaneous coronary intervention (PCI) procedures. The significant rise in prevalence of cardiovascular diseases and growing elderly population, more prone to cardiac conditions, drive the necessity of the Eptifibatide worldwide. The advancements in percutaneous coronary intervention (PCI) techniques drive the innovation in the utilization of Eptifibatide. The favorable reimbursement policies and increased healthcare expenditure also significantly contribute to market expansion. Despite the growth prospects, significant side effect profiles associated with Eptifibatide, such as bleeding risks, may hinder its adoption in the market arena. The compliance with stringent regulatory standards also poses a substantial challenge for the market expansion. Moreover, continuous advancements in drug formulation and delivery techniques also spotlight potential areas for development and growth. Ongoing R&D initiatives to explore synergistic combinations of Eptifibatide with other antiplatelet agents can pave new paths for product penetration in the market space.

KEY MARKET STATISTICS
Base Year [2023] USD 389.82 million
Estimated Year [2024] USD 411.06 million
Forecast Year [2030] USD 577.29 million
CAGR (%) 5.76%

Type: Increasing preference of 2 mg/ml formulation for acute administration

The 0.75mg/ml of Eptifibatide is generally used for continuous infusion over a period, often starting with a bolus dose followed by maintenance dosing. 0.75mg/ml is particularly suited for patients that require a lower dose due to specific clinical factors such as weight or renal function. The 0.75mg/ml solution allows for precise dosing adjustments and is commonly preferred in treatment protocols that necessitate gradual escalation or reduction of the antiplatelet effect. The Eptifibatide's 2mg/ml formulation is designed for acute administration, particularly in high-stress scenarios requiring rapid platelet inhibition, such as during or immediately after percutaneous coronary interventions (PCI). The higher concentration enables quicker administration of a bolus dose, followed by a maintenance infusion that can be adjusted based on clinical response and patient condition.

Application: Diverse scope of applications in myocardial infarction

Eptifibatide is administered as part of the therapeutic regimen to prevent further clot formation, thus reducing the risk of subsequent cardiovascular events. The need-based preference for Eptifibatide in myocardial infarction cases stems from its effectiveness in enhancing patient outcomes during percutaneous coronary intervention (PCI). Unstable Angina, a type of chest pain caused by reduced blood flow to the heart, is another critical application area for Eptifibatide. Similar to MI, Eptifibatide's role is centered on preventing platelet aggregation, thus mitigating the risk of a heart attack.

Regional Insights

In the Americas, particularly the United States and Canada, the usage of Eptifibatide is significantly influenced by the advanced healthcare infrastructure and high prevalence of cardiovascular diseases. In the United States and Canada, patent cliffs have led to increased availability of generic versions, impacting customers' purchasing behaviors in the region. The European Union (EU) exhibits a high demand for Eptifibatide largely due to the aging population and the consequent rise in cardiovascular diseases. European countries have a robust healthcare system and initiatives to reduce healthcare expenditure, which influences the Eptifibatide market dynamics. Due to its relatively better healthcare infrastructure and higher income levels, the Middle East region shows a growing demand for advanced therapeutic options including Eptifibatide. Limited healthcare facilities and affordability issues constrain the African market for the adoption of eptifibatide. In the Asia Pacific region, countries such as China, Japan, and India are pivotal in the Eptifibatide market due to their large populations and increasing incidence of cardiovascular diseases. China's market is growing rapidly, influenced by government initiatives to improve healthcare and boost the local production of pharmaceuticals, including Eptifibatide. With its advanced healthcare system, Japan continues to be a significant consumer, focusing on innovative treatment solutions. India's market is characterized by growing healthcare awareness and affordability issues, with generic drugs contributing to the market growth in the APAC region.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Eptifibatide Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Eptifibatide Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Eptifibatide Market, highlighting leading vendors and their innovative profiles. These include Accord Healthcare, Amneal Pharmaceuticals LLC, Baxter International Inc., Eugia US LLC, GlaxoSmithKline PLC, Hybio Pharmaceutical Co., Ltd., Kensington Pharma, Merck & Co., Inc., Novetide Ltd., Sagent Pharmaceuticals, Slate Run Pharmaceuticals, Strides Pharma Canada Inc., and Taj Pharmaceuticals.

Market Segmentation & Coverage

This research report categorizes the Eptifibatide Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Type
    • 0.75mg/ml Eptifibatide
    • 2mg/ml Eptifibatide
  • Application
    • Myocardial Infarction
    • Unstable Angina
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Eptifibatide Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Eptifibatide Market?

3. What are the technology trends and regulatory frameworks in the Eptifibatide Market?

4. What is the market share of the leading vendors in the Eptifibatide Market?

5. Which modes and strategic moves are suitable for entering the Eptifibatide Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising prevalence of cardiovascular diseases and growing elderly population, more prone to cardiac conditions
      • 5.1.1.2. Ongoing advancements in percutaneous coronary intervention (PCI) techniques
      • 5.1.1.3. Increased healthcare expenditure and favorable reimbursement policies
    • 5.1.2. Restraints
      • 5.1.2.1. Side effect and safety risks associated with use of Eptifibatide
    • 5.1.3. Opportunities
      • 5.1.3.1. Continuous advancements in drug formulation and delivery techniques
      • 5.1.3.2. Ongoing R&D initiatives to explore synergistic combinations with other antiplatelet agents
    • 5.1.4. Challenges
      • 5.1.4.1. Compliance with stringent regulatory standards
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Type: Increasing preference of 2 mg/ml formulation for acute administration
    • 5.2.2. Application: Diverse scope of applications in myocardial infarction
  • 5.3. Market Disruption Analysis
  • 5.4. Porter's Five Forces Analysis
    • 5.4.1. Threat of New Entrants
    • 5.4.2. Threat of Substitutes
    • 5.4.3. Bargaining Power of Customers
    • 5.4.4. Bargaining Power of Suppliers
    • 5.4.5. Industry Rivalry
  • 5.5. Value Chain & Critical Path Analysis
  • 5.6. Pricing Analysis
  • 5.7. Technology Analysis
  • 5.8. Patent Analysis
  • 5.9. Trade Analysis
  • 5.10. Regulatory Framework Analysis

6. Eptifibatide Market, by Type

  • 6.1. Introduction
  • 6.2. 0.75mg/ml Eptifibatide
  • 6.3. 2mg/ml Eptifibatide

7. Eptifibatide Market, by Application

  • 7.1. Introduction
  • 7.2. Myocardial Infarction
  • 7.3. Unstable Angina

8. Americas Eptifibatide Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific Eptifibatide Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa Eptifibatide Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. Market Share Analysis, 2023
  • 11.2. FPNV Positioning Matrix, 2023
  • 11.3. Competitive Scenario Analysis
    • 11.3.1. Anti-platelet Therapy Could Help Improve Outcomes For Patients With a Deadly Form of Brain Bleed, New Study Reveals
    • 11.3.2. Juno Pharmaceuticals Receives Approval to Import Eptifibatide as Canadian Hospitals Continue to Grapple with Shortages of Critical Medicines
  • 11.4. Strategy Analysis & Recommendation

12. Competitive Portfolio

  • 12.1. Key Company Profiles
  • 12.2. Key Product Portfolio

LIST OF FIGURES

  • FIGURE 1. EPTIFIBATIDE MARKET RESEARCH PROCESS
  • FIGURE 2. EPTIFIBATIDE MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL EPTIFIBATIDE MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL EPTIFIBATIDE MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. GLOBAL EPTIFIBATIDE MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. EPTIFIBATIDE MARKET DYNAMICS
  • FIGURE 7. GLOBAL EPTIFIBATIDE MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 8. GLOBAL EPTIFIBATIDE MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL EPTIFIBATIDE MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 10. GLOBAL EPTIFIBATIDE MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. AMERICAS EPTIFIBATIDE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 12. AMERICAS EPTIFIBATIDE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. UNITED STATES EPTIFIBATIDE MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 14. UNITED STATES EPTIFIBATIDE MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. ASIA-PACIFIC EPTIFIBATIDE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 16. ASIA-PACIFIC EPTIFIBATIDE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. EUROPE, MIDDLE EAST & AFRICA EPTIFIBATIDE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA EPTIFIBATIDE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. EPTIFIBATIDE MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 20. EPTIFIBATIDE MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. EPTIFIBATIDE MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL EPTIFIBATIDE MARKET SIZE, 2018-2023 (USD MILLION)
  • TABLE 4. GLOBAL EPTIFIBATIDE MARKET SIZE, 2024-2030 (USD MILLION)
  • TABLE 5. GLOBAL EPTIFIBATIDE MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 6. GLOBAL EPTIFIBATIDE MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 7. GLOBAL EPTIFIBATIDE MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 8. GLOBAL EPTIFIBATIDE MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 9. GLOBAL EPTIFIBATIDE MARKET SIZE, BY 0.75MG/ML EPTIFIBATIDE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 10. GLOBAL EPTIFIBATIDE MARKET SIZE, BY 0.75MG/ML EPTIFIBATIDE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 11. GLOBAL EPTIFIBATIDE MARKET SIZE, BY 2MG/ML EPTIFIBATIDE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 12. GLOBAL EPTIFIBATIDE MARKET SIZE, BY 2MG/ML EPTIFIBATIDE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 13. GLOBAL EPTIFIBATIDE MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 14. GLOBAL EPTIFIBATIDE MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 15. GLOBAL EPTIFIBATIDE MARKET SIZE, BY MYOCARDIAL INFARCTION, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 16. GLOBAL EPTIFIBATIDE MARKET SIZE, BY MYOCARDIAL INFARCTION, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 17. GLOBAL EPTIFIBATIDE MARKET SIZE, BY UNSTABLE ANGINA, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 18. GLOBAL EPTIFIBATIDE MARKET SIZE, BY UNSTABLE ANGINA, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 19. AMERICAS EPTIFIBATIDE MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 20. AMERICAS EPTIFIBATIDE MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 21. AMERICAS EPTIFIBATIDE MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 22. AMERICAS EPTIFIBATIDE MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 23. AMERICAS EPTIFIBATIDE MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 24. AMERICAS EPTIFIBATIDE MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 25. ARGENTINA EPTIFIBATIDE MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 26. ARGENTINA EPTIFIBATIDE MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 27. ARGENTINA EPTIFIBATIDE MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 28. ARGENTINA EPTIFIBATIDE MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 29. BRAZIL EPTIFIBATIDE MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 30. BRAZIL EPTIFIBATIDE MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 31. BRAZIL EPTIFIBATIDE MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 32. BRAZIL EPTIFIBATIDE MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 33. CANADA EPTIFIBATIDE MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 34. CANADA EPTIFIBATIDE MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 35. CANADA EPTIFIBATIDE MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 36. CANADA EPTIFIBATIDE MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 37. MEXICO EPTIFIBATIDE MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 38. MEXICO EPTIFIBATIDE MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 39. MEXICO EPTIFIBATIDE MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 40. MEXICO EPTIFIBATIDE MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 41. UNITED STATES EPTIFIBATIDE MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 42. UNITED STATES EPTIFIBATIDE MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 43. UNITED STATES EPTIFIBATIDE MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 44. UNITED STATES EPTIFIBATIDE MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 45. UNITED STATES EPTIFIBATIDE MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
  • TABLE 46. UNITED STATES EPTIFIBATIDE MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
  • TABLE 47. ASIA-PACIFIC EPTIFIBATIDE MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 48. ASIA-PACIFIC EPTIFIBATIDE MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 49. ASIA-PACIFIC EPTIFIBATIDE MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 50. ASIA-PACIFIC EPTIFIBATIDE MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 51. ASIA-PACIFIC EPTIFIBATIDE MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 52. ASIA-PACIFIC EPTIFIBATIDE MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 53. AUSTRALIA EPTIFIBATIDE MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 54. AUSTRALIA EPTIFIBATIDE MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 55. AUSTRALIA EPTIFIBATIDE MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 56. AUSTRALIA EPTIFIBATIDE MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 57. CHINA EPTIFIBATIDE MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 58. CHINA EPTIFIBATIDE MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 59. CHINA EPTIFIBATIDE MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 60. CHINA EPTIFIBATIDE MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 61. INDIA EPTIFIBATIDE MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 62. INDIA EPTIFIBATIDE MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 63. INDIA EPTIFIBATIDE MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 64. INDIA EPTIFIBATIDE MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 65. INDONESIA EPTIFIBATIDE MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 66. INDONESIA EPTIFIBATIDE MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 67. INDONESIA EPTIFIBATIDE MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 68. INDONESIA EPTIFIBATIDE MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 69. JAPAN EPTIFIBATIDE MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 70. JAPAN EPTIFIBATIDE MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 71. JAPAN EPTIFIBATIDE MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 72. JAPAN EPTIFIBATIDE MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 73. MALAYSIA EPTIFIBATIDE MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 74. MALAYSIA EPTIFIBATIDE MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 75. MALAYSIA EPTIFIBATIDE MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 76. MALAYSIA EPTIFIBATIDE MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 77. PHILIPPINES EPTIFIBATIDE MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 78. PHILIPPINES EPTIFIBATIDE MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 79. PHILIPPINES EPTIFIBATIDE MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 80. PHILIPPINES EPTIFIBATIDE MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 81. SINGAPORE EPTIFIBATIDE MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 82. SINGAPORE EPTIFIBATIDE MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 83. SINGAPORE EPTIFIBATIDE MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 84. SINGAPORE EPTIFIBATIDE MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 85. SOUTH KOREA EPTIFIBATIDE MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 86. SOUTH KOREA EPTIFIBATIDE MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 87. SOUTH KOREA EPTIFIBATIDE MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 88. SOUTH KOREA EPTIFIBATIDE MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 89. TAIWAN EPTIFIBATIDE MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 90. TAIWAN EPTIFIBATIDE MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 91. TAIWAN EPTIFIBATIDE MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 92. TAIWAN EPTIFIBATIDE MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 93. THAILAND EPTIFIBATIDE MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 94. THAILAND EPTIFIBATIDE MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 95. THAILAND EPTIFIBATIDE MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 96. THAILAND EPTIFIBATIDE MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 97. VIETNAM EPTIFIBATIDE MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 98. VIETNAM EPTIFIBATIDE MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 99. VIETNAM EPTIFIBATIDE MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 100. VIETNAM EPTIFIBATIDE MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 101. EUROPE, MIDDLE EAST & AFRICA EPTIFIBATIDE MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA EPTIFIBATIDE MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA EPTIFIBATIDE MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA EPTIFIBATIDE MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA EPTIFIBATIDE MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA EPTIFIBATIDE MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 107. DENMARK EPTIFIBATIDE MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 108. DENMARK EPTIFIBATIDE MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 109. DENMARK EPTIFIBATIDE MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 110. DENMARK EPTIFIBATIDE MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 111. EGYPT EPTIFIBATIDE MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 112. EGYPT EPTIFIBATIDE MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 113. EGYPT EPTIFIBATIDE MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 114. EGYPT EPTIFIBATIDE MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 115. FINLAND EPTIFIBATIDE MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 116. FINLAND EPTIFIBATIDE MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 117. FINLAND EPTIFIBATIDE MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 118. FINLAND EPTIFIBATIDE MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 119. FRANCE EPTIFIBATIDE MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 120. FRANCE EPTIFIBATIDE MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 121. FRANCE EPTIFIBATIDE MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 122. FRANCE EPTIFIBATIDE MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 123. GERMANY EPTIFIBATIDE MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 124. GERMANY EPTIFIBATIDE MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 125. GERMANY EPTIFIBATIDE MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 126. GERMANY EPTIFIBATIDE MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 127. ISRAEL EPTIFIBATIDE MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 128. ISRAEL EPTIFIBATIDE MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 129. ISRAEL EPTIFIBATIDE MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 130. ISRAEL EPTIFIBATIDE MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 131. ITALY EPTIFIBATIDE MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 132. ITALY EPTIFIBATIDE MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 133. ITALY EPTIFIBATIDE MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 134. ITALY EPTIFIBATIDE MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 135. NETHERLANDS EPTIFIBATIDE MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 136. NETHERLANDS EPTIFIBATIDE MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 137. NETHERLANDS EPTIFIBATIDE MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 138. NETHERLANDS EPTIFIBATIDE MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 139. NIGERIA EPTIFIBATIDE MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 140. NIGERIA EPTIFIBATIDE MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 141. NIGERIA EPTIFIBATIDE MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 142. NIGERIA EPTIFIBATIDE MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 143. NORWAY EPTIFIBATIDE MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 144. NORWAY EPTIFIBATIDE MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 145. NORWAY EPTIFIBATIDE MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 146. NORWAY EPTIFIBATIDE MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 147. POLAND EPTIFIBATIDE MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 148. POLAND EPTIFIBATIDE MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 149. POLAND EPTIFIBATIDE MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 150. POLAND EPTIFIBATIDE MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 151. QATAR EPTIFIBATIDE MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 152. QATAR EPTIFIBATIDE MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 153. QATAR EPTIFIBATIDE MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 154. QATAR EPTIFIBATIDE MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 155. RUSSIA EPTIFIBATIDE MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 156. RUSSIA EPTIFIBATIDE MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 157. RUSSIA EPTIFIBATIDE MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 158. RUSSIA EPTIFIBATIDE MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 159. SAUDI ARABIA EPTIFIBATIDE MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 160. SAUDI ARABIA EPTIFIBATIDE MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 161. SAUDI ARABIA EPTIFIBATIDE MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 162. SAUDI ARABIA EPTIFIBATIDE MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 163. SOUTH AFRICA EPTIFIBATIDE MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 164. SOUTH AFRICA EPTIFIBATIDE MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 165. SOUTH AFRICA EPTIFIBATIDE MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 166. SOUTH AFRICA EPTIFIBATIDE MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 167. SPAIN EPTIFIBATIDE MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 168. SPAIN EPTIFIBATIDE MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 169. SPAIN EPTIFIBATIDE MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 170. SPAIN EPTIFIBATIDE MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 171. SWEDEN EPTIFIBATIDE MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 172. SWEDEN EPTIFIBATIDE MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 173. SWEDEN EPTIFIBATIDE MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 174. SWEDEN EPTIFIBATIDE MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 175. SWITZERLAND EPTIFIBATIDE MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 176. SWITZERLAND EPTIFIBATIDE MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 177. SWITZERLAND EPTIFIBATIDE MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 178. SWITZERLAND EPTIFIBATIDE MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 179. TURKEY EPTIFIBATIDE MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 180. TURKEY EPTIFIBATIDE MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 181. TURKEY EPTIFIBATIDE MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 182. TURKEY EPTIFIBATIDE MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 183. UNITED ARAB EMIRATES EPTIFIBATIDE MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 184. UNITED ARAB EMIRATES EPTIFIBATIDE MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 185. UNITED ARAB EMIRATES EPTIFIBATIDE MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 186. UNITED ARAB EMIRATES EPTIFIBATIDE MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 187. UNITED KINGDOM EPTIFIBATIDE MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 188. UNITED KINGDOM EPTIFIBATIDE MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 189. UNITED KINGDOM EPTIFIBATIDE MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 190. UNITED KINGDOM EPTIFIBATIDE MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 191. EPTIFIBATIDE MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 192. EPTIFIBATIDE MARKET, FPNV POSITIONING MATRIX, 2023